

Dmitry E Karateev

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3521752/dmitry-e-karateev-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41
papers

2,345
citations

9
h-index

48
g-index

56
ext. papers

2,776
ext. citations

1.4
avg, IF

3.61
L-index

#	Paper	IF	Citations
41	The role of targeted synthetic drugs in the treatment of rheumatic diseases: focus on tofacitinib. <i>Meditsinskiy Sovet</i> , 2020 , 83-94	0.4	1
40	Evaluation of PhysiciansSKnowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing. <i>Biomolecules</i> , 2019 , 9,	5.9	4
39	New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab. <i>Alʹmanah Kliničeskoj Mediciny</i> , 2019 , 47, 461-469	0.2	1
38	The rs7574865 polymorphism of the STAT4 gene and risk of early rheumatoid arthritis development (the REMARKA study). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019 , 57, 62-65	0.9	1
37	The use of subcutaneous methotrexate from various manufacturers in real clinical practice: a comparative study. <i>Alʹmanah Kliničeskoj Mediciny</i> , 2019 , 47, 383-392	0.2	1
36	Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis. <i>Meditsinskiy Sovet</i> , 2019 , 85-91	0.4	
35	Calcification of coronary arteries in early rheumatoid arthritis prior to anti-rheumatic therapy. <i>Rheumatology International</i> , 2018 , 38, 211-217	3.6	7
34	MOLECULAR GENETIC TESTING OF ACCP-POSITIVE PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGH INFLAMMATORY DISEASE ACTIVITY (A REMARCA STUDY). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2018 , 56, 28-33	0.9	3
33	Efficacy and tolerability of abatacept treatment: results of 12 months observation. <i>Terapevticheskii Arkhiv</i> , 2018 , 90, 44-49	0.9	2
32	Association of polymorphisms of HLA-DRB1 and TNF-308 G/A with radiographic joint damage in patients with early rheumatoid arthritis with high inflammatory activity, treated according to the principle of "Treat to target" (REMARKA study). <i>Terapevticheskii Arkhiv</i> , 2018 , 90, 38-43	0.9	1
31	PROGRESSION OF CAROTID ARTERY ATHEROSCLEROSIS DURING TREATMENT TO TARGET IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2018 , 56, 449-455	0.9	4
30	Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 149, 278-289	3.5	3
29	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-974	27.4	1649
28	Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. <i>Rheumatology International</i> , 2017 , 37, 1469-1479	3.6	12
27	Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1469-1480	2.3	6
26	PAIN AND INFLAMMATION. PART 2. THE ANALGESIC POTENTIAL OF ANTI-INFLAMMATORY DRUGS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2017 , 55, 58-67	0.9	6
25	Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies). <i>Sovremennaya Revmatologiya</i> , 2017 , 11, 14-25	0.7	4

24	MODERN PRINCIPLES OF MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Meditsinskiy Sovet</i> , 2017 , 92-100	0.4	1
23	RUSSIAN AND INTERNATIONAL EXPERIENCE IN THE APPLICATION OF THE JANUS-KINASES INHIBITOR IN RHEUMATOID ARTHRITIS. <i>Meditsinskiy Sovet</i> , 2017 , 87-92	0.4	2
22	ISSUES OF OPTIMIZATION OF METHOTREXATE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2017 , 55, 41-47	0.9	2
21	THE EFFECT OF ABATACEPT ON BLOOD BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2017 , 55, 368-375	0.9	1
20	RESOLUTION OF THE EXPERT MEETING ON INCREASING THE AVAILABILITY OF INNOVATIVE TREATMENTS FOR PATIENTS WITH SPONDYLOARTHRITIS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2017 , 55, 457-459	0.9	1
19	INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2016 , 54, 21-30	0.9	4
18	USE OF SUBCUTANEOUS METHOTREXATE FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: THE REMARCA TRIAL. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2016 , 54, 138-144	0.9	3
17	Efficacy and safety of Tofacitinib in patients with active rheumatoid arthritis resistant to conventional therapy: Preliminary results of an open-label clinical trial. <i>Sovremennaya Revmatologiya</i> , 2016 , 10, 17-23	0.7	3
16	The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis. <i>Journal of Korean Medical Science</i> , 2016 , 31, 202-7	4.7	39
15	Biothérapies en rhumatologie en Amérique Latine, en Europe, en Russie et en Inde : produits innovants, biosimilaires et profondes copies. <i>Revue Du Rhumatisme (Edition Française)</i> , 2015 , 82, 150-156 ^{0.1}		
14	RHEUMATOID ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO RUSSIAN ARTHRITIS REGISTRY DATA (COMMUNICATION I). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2015 , 53, 472-484	0.9	12
13	PROJECT: RECOMMENDATIONS ON TREATMENT OF RHEUMATOID ARTHRITIS DEVELOPED BY ALL-RUSSIAN PUBLIC ORGANIZATION «ASSOCIATION OF RHEUMATOLOGISTS OF RUSSIA» 2014 (PART 1). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2015 , 53, 1-17	0.9	3
12	Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. <i>Joint Bone Spine</i> , 2014 , 81, 471-7	2.9	39
11	CARDIOVASCULAR RISK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS BEFORE DISEASE-MODIFYING ANTIRHEUMATIC THERAPY (PRELIMINARY DATA OF THE REMARCA STUDY). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2014 , 381	0.9	3
10	THE FIRST RUSSIAN STRATEGIC STUDY OF PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS (REMARCA TRIAL): RESULTS OF 12-MONTH TREATMENT IN 130 PATIENTS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2014 , 607	0.9	7
9	Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. <i>International Journal of Rheumatology</i> , 2013 , 2013, 457876	2	14
8	Use of genetically engineered biological agents for the treatment of rheumatoid arthritis: general characteristics (a lecture). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2013 , 163	0.9	4
7	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 495-502	2.4	117

6	Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1666-72	2.4	120
5	Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2009 , 11, R7	5.7	233
4	Immunomodulatory drug therapy for the disease caused by SARS-CoV-2 infection (COVID-19). <i>Alʹmanah Kliničeskoj Mediciny</i> , 48, 51-67	0.2	0
3	Comorbidities and predicting the outcome of COVID-19: the treatment results of 13,585 patients hospitalized in the Moscow Region. <i>Alʹmanah Kliničeskoj Mediciny</i> , 48, 1-10	0.2	7
2	Comorbidities and predicting the outcome of COVID-19: the treatment results of 13,585 patients hospitalized in the Moscow Region. <i>Alʹmanah Kliničeskoj Mediciny</i> , 48, 1-10	0.2	1
1	PROJECT: RECOMMENDATIONS ON TREATMENT OF RHEUMATOID ARTHRITIS DEVELOPED BY ALL-RUSSIAN PUBLIC ORGANIZATION «ASSOCIATION OF RHEUMATOLOGISTS OF RUSSIA» 2014 (PART 1). <i>Nauchno-Praktičeskaya Revmatologiya</i> , 54, 1-17	0.9	6